Crizotinib attenuates bleomycin-induced pulmonary fibrosis via regulating fibroblast activation - PubMed
7 hours ago
- #crizotinib
- #pulmonary fibrosis
- #fibroblast activation
- Crizotinib, a tyrosine kinase inhibitor, shows potential in attenuating bleomycin-induced pulmonary fibrosis by regulating fibroblast activation.
- The study explores crizotinib's antifibrotic effects both in vitro (TGF-β1 stimulated fibroblasts) and in vivo (bleomycin-induced pulmonary fibrosis in mice).
- In vitro results indicate crizotinib reduces expression of fibrotic markers (Fn, Col-1, α-SMA) and inhibits fibroblast activation and migration.
- In vivo, crizotinib improves lung function, reduces fibrotic lesions, and decreases expression of fibrotic factors in lung tissues.
- Crizotinib's mechanism involves inhibition of key signaling pathways (PI3K/AKT/mTOR, STAT3, ERK) associated with pulmonary fibrosis progression.
- The findings suggest crizotinib could be a promising therapeutic option for idiopathic pulmonary fibrosis (IPF) patients.